Last reviewed · How we verify
NCT05874635
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
NA trial testing Continuous Glucose Monitor Device in Weight Loss in 20,000 participants. Participants enrolled and being followed up; not accepting new ones.
10 May 2028
Quick facts
| Lead sponsor | Signos Inc |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20,000 |
| Start date | 11 May 2023 |
| Primary completion | 10 May 2028 |
| Estimated completion | 10 May 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Continuous Glucose Monitor Device
Conditions studied
- Weight Loss — all drugs for Weight Loss →
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
- Central Obesity — all drugs for Central Obesity →
Sponsor
Signos Inc
Who can join
18 and older, any sex, with Weight Loss or Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and the Signos mHealth platform will assist with weight control in a population of people with type 2 diabetes mellitus who are not using insulin.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05874635
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Continuous Glucose Monitor Device
Trials testing the same drug.
- NCT05121844 — Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform · NA · active not recruiting
Other recruiting trials for Weight Loss
Currently open trials in the same condition.
- NCT06811324 — Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults · Phase 2 · recruiting
- NCT07223983 — Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) · Phase 1 · recruiting
- NCT07213466 — Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder · Phase 4 · recruiting
- NCT06785064 — Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance · NA · recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
Other Signos Inc trials
Trials by the same sponsor.
- NCT06214221 — Using Signos mHealth Platform in Adults for Weight Management · NA · active not recruiting
- NCT05121844 — Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05874635 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Signos Inc
- Last refreshed: 29 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05874635.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing